BackNovozymes A/S Overview

Novozymes A/S Accounts Payable

Track Novozymes A/S's accounts payable ($370M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$370.70M
↑ 23.92% YoYΔ $71.55M vs prior year quarter

Peer trimmed avg / median

Loading

Novozymes A/S Accounts Payable History

Loading

Novozymes A/S vs. peers: Accounts Payable Comparison

Loading

Novozymes A/S Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Novozymes A/S (NVZMF) FAQ

The latest accounts payable for NVZMF is $370M as of September 2026. That compares with $300M in the prior-year period — up 23.9% year over year. Investors often review this figure alongside Novozymes A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVZMF's accounts payable moved from $300M to $370M — a 23.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novozymes A/S's operating scale or balance-sheet position.

A accounts payable figure of $370M for NVZMF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NVZMF's accounts payable ($370M), review year-over-year change from $300M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.